Opinion
Premier Scientific Journal Nature Takes on ‘Climate of Fear’ Surrounding Research on Sex and Genr
From Heartland Daily News
“These articles are using phrases like ‘a person’s sex assigned at birth’. I find that phrase amusing. I don’t think sex is assigned at birth. Biological sex is a fact. It’s not assigned. It’s observed.”
Nature, one of the world’s premier scientific journals, has acknowledged the importance of studying sex and gender differences and officially denounced the “climate of fear and reticence” that is stymying research on the topic.
To that end, the journal in May launched “a collection of opinion articles” on the topic to be published over the coming months to foster honest and courageous discussions on a topic that many scientists shy away from due to fears of professional and personal repercussions.
“Some scientists have been warned off studying sex differences by colleagues. Others, who are already working on sex or gender-related topics, are hesitant to publish their views,” read the editorial introducing the series.
“…In time, we hope this collection will help to shape research, and provide a reference point for moderating often-intemperate debates.”
Headlines that kicked off the series include “Neglecting sex and gender in research is a public-health risk,” “Male–female comparisons are powerful in biomedical research” and “Heed lessons from past studies involving transgender people: first, do no harm.”
What the collection of articles represents and whether it will ease tensions surrounding this area of research remains to be seen.
Jeffrey Mogil, a neuroscientist and pain researcher at Mcgill University, as well as the co-author of one of the articles in Nature’s sex and gender series, told The College Fix there is an effort underway in biological research to do away with or minimize the importance of the concept of sex and sex as a binary variable.
This is problematic, Mogil said in a recent telephone interview, because sex in mammals is “either binary or it rounds to binary and in doing so it always has been useful and continues to be and any conception of it that isn’t binary would then impose practical difficulties on how science is done.”
Moreover, he noted, discarding the notion of binary sex in mammals would set back important advancements in how many biomedical researchers now do their work.
“There are sex differences in all kinds of traits that we’re interested in and where we didn’t know they existed,” Mogil said. “The reason we didn’t know they existed [is] because until extremely recently, essentially all biology pre-clinical experiments were done with males only.”
“Since regulatory agencies, funding agencies, have demanded that people start using both sexes [in research],” he said, “lo and behold, we’re finding sex differences.”
“We’re finding that what we thought was the biology of a thing was only the biology of the thing in males and the female biology is completely different,” he added.
“This is in our minds,” he said, “an incredible scientific advance and that advance is at risk of stopping and reverting if, you know, people start to believe…dividing animals into males and females is inappropriate.”
Although Mogil stated he did not know how Nature made editorial decisions regarding the selection of articles for their sex and gender collection, he said that he felt the article he and his co-authors wrote was intended to defend the status quo against those “advocating…either that gender is much more important than sex or that sex is more complicated than people have made it seem.”
The College Fix reached out to a senior communications manager from Springer Nature in early June regarding the selection process for the series, as well as how sex was presented in some of the other commentaries, but did not receive a response.
Daniel Barbash, a professor of molecular biology and genetics at Cornell University, was more skeptical than Mogil of Nature’s sex and gender op-ed collection when he spoke to The College Fix in a late-May phone interview.
Although he said he generally held a positive view of the article Mogil co-authored and appreciated that it explicitly stated “there are only two sex categories in mammals,” he noted that he also felt the authors of other commentaries in the series were to some extent “further conflating sex and gender.”
“There’s little things that sometimes give the game away,” he said. “These articles are using phrases like ‘a person’s sex assigned at birth’. I find that phrase amusing. I don’t think sex is assigned at birth. Biological sex is a fact. It’s not assigned. It’s observed.”
“[For] the vast majority of humans, from the moment they’re born,” he said, “there is zero ambiguity whether they’re a male or a female.”
Furthermore, the “overall tone” of the collection, Barbash said, was that “there needs to be more research on gender variation and that there is more complexity to biological sex than a binary.”
According to Barbash, neither of these notions are “universally accepted” among biologists.
He said he believes the series has “the potential to drive funding agencies and other agencies that are involved in the intersection between politics and research in a particular direction that I don’t think would always be helpful.”
“I don’t think any serious biologist would deny that sex is a hugely important factor in both basic research and in biomedical research,” said Barbash. “Of course, any study on the effect of drugs should be tested separately in males and females, otherwise it’s a hugely confounding factor if you ignore that.”
Yet, he said, “the notion that we need to do the same thing for gender…is really not supported,” and may not be very feasible.
“Half the population is male and half the population is female,” Barbash said. “We see all kinds of estimates for gender nonconforming and transgender individuals but, no doubt, they’re much less frequent than males and females.”
On account of this, he said, even if research questions regarding gender divergence and transgender individuals are worthwhile, “it would be problematic, for example, to necessitate that all NIH studies of humans include males, females and gender nonconforming individuals or transgender individuals.”
However, he said, he feared “this series of articles could have that kind of impact in influencing policy.”
Originally published by The College Fix. Republished with permission.
Daily Caller
‘There Will Be Very Serious Retaliation’: Two American Servicemen, Interpreter Killed In Syrian Attack

From the Daily Caller News Foundation
Two U.S. Army soldiers and an American civilian interpreter were killed in a Saturday attack in Syria, the Department of War announced.
Sean Parnell, chief spokesman for the Pentagon, announced the three deaths in a statement posted to X, adding that three others were wounded. The attack occurred as the U.S. soldiers were conducting a “key leader engagement,” Parnell stated.
The soldiers’ mission was “in support of on-going counter-ISIS/counter-terrorism operations in the region,” Parnell wrote. The attack occurred in an area Syrian President Ahmed al-Sharaa does not have control, Fox News reported, citing a Pentagon official.
Dear Readers:
As a nonprofit, we are dependent on the generosity of our readers.
Please consider making a small donation of any amount here.
Thank you!
“The soldiers’ names, as well as identifying information about their units, are being withheld until 24 hours after the next of kin notification,” he continued. “This attack is currently under active investigation.”
Secretary of War Pete Hegseth said in a Saturday statement posted on X that the “savage” who perpetrated the attack was “killed by partner forces.”
“Let it be known, if you target Americans — anywhere in the world — you will spend the rest of your brief, anxious life knowing the U.S. will hunt you, find you, and ruthlessly kill you,” Hegseth wrote.
U.S. and Syrian forces came under attack Saturday amid a joint patrol near Palmyra, The New York Times reported, citing Syrian state news agency SANA. U.S. Central Command also confirmed the deaths in a Saturday X post, but noted additional updates about the incident will be provided as they become available.
President Trump responded to the attack on Truth Social:
We mourn the loss of three Great American Patriots in Syria, two soldiers, and one Civilian Interpreter. Likewise, we pray for the three injured soldiers who, it has just been confirmed, are doing well. This was an ISIS attack against the U.S., and Syria, in a very dangerous part of Syria, that is not fully controlled by them. The President of Syria, Ahmed al-Sharaa, is extremely angry and disturbed by this attack. There will be very serious retaliation. Thank you for your attention to this matter!
Health
The Data That Doesn’t Exist
ACIP voted to un-recommend the Hep B birth dose, but here’s the problem: they still can’t weigh the other side of the ledger
Sunday, something happened that has never happened in the history of American public health: ACIP voted 8-3 to un-recommend the universal birth dose of hepatitis B for babies born to mothers who test negative for the virus. After 34 years of jabbing every American newborn within hours of taking their first breath—regardless of whether their mother had hepatitis B—the committee finally acknowledged what 25 European countries figured out decades ago: it doesn’t make sense.
But watching this vote unfold, I couldn’t help but notice the absurdity of the debate itself. Committee members who opposed the change kept saying variations of the same thing: “We’ve heard ‘do no harm’ as a moral imperative. We are doing harm by changing this wording.” Another said “no rational science has been presented” to support the change.
How to End the Autism Epidemic is a reader-supported publication.
To receive new posts and support my work, consider becoming a free or paid subscriber.
And therein lies the fundamental problem with ACIP—and with the entire vaccine regulatory apparatus in America. They literally cannot weigh risk versus benefit because they only have data on one side of the scale.
The Missing Side of the Ledger
When ACIP debates adding or removing a vaccine from the schedule, they can produce endless data on disease incidence. They can show you charts demonstrating how hepatitis B cases in infants dropped from thousands to single digits after 1991. They can model projected infections if vaccination rates decline. They have this data at their fingertips because tracking infectious disease is something our public health apparatus actually does.
But ask them to produce equivalent data on vaccine injury, and you’ll get silence. Not “the data shows injuries are rare.” Not “here’s our comprehensive tracking of adverse events.” Just… nothing. A void where information should be.
This is not an accident. This is by design.
The safety trials for Engerix-B and Recombivax HB—the two hepatitis B vaccines given to American newborns—monitored adverse events for four to five days after injection. That’s it. If your baby developed seizures on day six, or regressed into autism over the following months, or developed autoimmune disease in the following year—none of that would appear in the pre-licensure safety data.
And the post-market surveillance? VAERS is a voluntary reporting system that the CDC itself acknowledges captures only a tiny fraction of adverse events. A Harvard-funded study found it captures perhaps 1% of actual vaccine injuries. Vaccine court has paid out over $5 billion in claims while simultaneously being structured to make filing nearly impossible for average families.
So when Dr. Cody Meissner voted against removing the Hep B birth dose and said he saw “clear evidence of the benefits” but “not the harms,” he was accidentally revealing the entire rotten structure. Of course he doesn’t see the harms. Nobody is systematically looking for them.
The Invisibility of Vaccine Injury
Here’s what most people don’t understand about vaccine injury: it’s nothing like a gunshot wound.
If you shoot someone, the cause is obvious. There’s a bullet, a wound, blood, a clear mechanism of action visible to any observer. Even a medical examiner who’s never seen the victim before can determine cause of death.
Vaccine injury doesn’t work that way. When aluminum nanoparticles from a vaccine cross the blood-brain barrier via macrophages, when they lodge in brain tissue and trigger chronic neuroinflammation, when a child slowly regresses over weeks or months—there’s no bullet. There’s no smoking gun. There’s just a before and an after, and a desperate parent trying to explain to doctors that something changed.
This invisibility is the vaccine program’s greatest protection. Because the injury mechanism is complex and delayed, because it doesn’t leave an obvious wound, because it requires actually looking to find—and because no one in authority is looking—the injuries simply don’t exist in the official record.
I watched my own son Jamie regress after his vaccines. A healthy, developing toddler who lost his words, stopped making eye contact, and retreated into a world we couldn’t reach. My wife and I know what happened. Thousands of other parents know the same thing happened to their children. But because this type of injury doesn’t show up on a simple blood test, because there’s no autopsy finding that says “vaccine-induced encephalopathy,” ACIP members can sit in a room and say with straight faces that they don’t see evidence of harm.
They’re not lying. They literally can’t see it. Because no one is measuring it.
The Chicken Pox Conundrum
Here’s an example that illustrates the insanity of our current approach.
The varicella (chicken pox) vaccine was added to the schedule in 1995. It definitely reduces chicken pox cases. The data is clear on that front. Mission accomplished, right?
But what about the other side of the ledger?
Emerging research suggests that wild chicken pox infection provides some protective effect against brain cancers—particularly glioma, the most common type of primary brain tumor. Multiple studies have found that people who had chicken pox as children have significantly lower rates of brain cancer later in life. The hypothesis is that the immune response to wild varicella provides lasting immunological benefits that extend far beyond preventing itchy spots.
Meanwhile, the vaccine itself has been associated with increased rates of autoimmune conditions. Studies have linked varicella vaccination to higher rates of herpes zoster (shingles) outbreaks in younger age groups, to autoimmune disorders, to various adverse events that weren’t captured in the original short-term safety trials.
So what’s the true risk-benefit of the chicken pox vaccine? Does preventing a week of itchy discomfort in childhood justify potentially increased rates of brain cancer and autoimmune disease later in life?
ACIP can’t answer this question. They literally don’t have the data. They can show you chicken pox cases going down. They cannot show you a comprehensive analysis of long-term neurological and immunological outcomes in vaccinated versus unvaccinated populations, because that study has never been done.
And so they keep recommending the vaccine based on the only data they have—the disease prevention data—while remaining willfully blind to consequences they’ve never bothered to measure.
The ACIP Paradox
Sunday’s vote was historic, but it also revealed the fundamental paradox of vaccine regulation in America.
The committee members who voted to remove the universal Hep B birth dose recommendation did so largely based on comparative evidence from Europe, parental concerns, and the basic logic that vaccinating a 12-hour-old baby for a sexually transmitted disease their mother doesn’t have makes no medical sense. They were right to do so.
But the committee members who voted against the change weren’t wrong either, from their perspective. They looked at the only data they have—disease prevention data—and concluded that removing the recommendation could lead to more hepatitis B cases. And within their limited framework, they’re correct.
The problem is the framework itself.
True risk-benefit analysis requires data on both risks AND benefits. ACIP has comprehensive data on benefits (disease prevention) and virtually no data on risks (vaccine injury). So every decision they make is fundamentally flawed from the start.
When Dr. Joseph Hibbeln complained that “no rational science has been presented” to support changing the recommendations, he was inadvertently indicting the entire system. Of course no comprehensive vaccine injury data was presented—such data doesn’t exist because no one has been willing to collect it.
This is like asking someone to make an informed financial decision while only showing them potential profits and hiding all possible losses. Of course the decision will be skewed. Of course you’ll end up with a bloated portfolio of high-risk investments that look great on paper.
The Real Reform
If RFK Jr. and the new HHS leadership want to actually fix the vaccine program, they need to understand that removing individual vaccines or making them “optional” is just rearranging deck chairs on the Titanic.
The real reform is creating the data infrastructure that should have existed from the beginning.
We need a comprehensive, long-term, vaccinated-versus-unvaccinated health outcomes study. Not a five-day safety trial. A multi-decade tracking of neurological, immunological, and developmental outcomes across populations with varying vaccination status. Florida just eliminated all vaccine mandates—that state alone could provide the data we need within ten years if someone had the courage to actually collect it.
We need a vaccine injury surveillance system that actually captures adverse events. Not a voluntary reporting system that misses 99% of injuries. An active surveillance system with trained clinicians looking for the kinds of delayed, complex injuries that vaccines actually cause.
We need accountability for manufacturers. The 1986 National Childhood Vaccine Injury Act removed all liability from vaccine makers—and predictably, the vaccine schedule exploded afterward while safety research stagnated. Why would any company invest in safety when they can’t be sued for injuries?
Without this data, every ACIP meeting will be the same performance we watched this week: members confidently citing disease prevention data while admitting they can’t see evidence of harm—not because harm doesn’t exist, but because no one is looking for it.
What Comes Next
Sunday’s vote was a crack in the wall. For the first time, an American regulatory body acknowledged that perhaps vaccinating every newborn within hours of birth for a disease primarily transmitted through sex and IV drug use doesn’t make sense when the mother has already tested negative.
But the forces of institutional inertia are already mobilizing. The American Academy of Pediatrics is “disappointed.” The American Medical Association is calling for the CDC to reject the recommendation. The pharmaceutical industry—which collects over $225 million annually from Hep B birth doses alone—will fight to restore the universal recommendation.
They will cite the same data they always cite: disease prevention data. Cases prevented. Infections avoided. Lives saved—theoretically.
They will not cite vaccine injury data, because that data doesn’t exist in any comprehensive form. They will not present long-term health outcomes in vaccinated versus unvaccinated children, because those studies have been actively avoided for decades. They will not acknowledge the thousands of families who have watched their children regress after vaccination, because those injuries aren’t captured in any official database.
And this is why ACIP will always be hamstrung. Until we build the data infrastructure to actually measure vaccine injury—to put real numbers on the other side of the ledger—every vaccine decision will be based on incomplete information. Every “risk-benefit analysis” will be a fraud, because we’re only measuring half the equation.
The hepatitis B birth dose vote was a small victory. But the larger battle—for actual science, for complete data, for true informed consent—that battle is just beginning.
And until we win it, ACIP will continue making decisions in the dark, confidently citing evidence of benefits while remaining deliberately blind to the harms they’ve never bothered to measure.
About the author
J.B. Handley is the proud father of a child with Autism. He spent his career in the private equity industry and received his undergraduate degree with honors from Stanford University. His first book, How to End the Autism Epidemic, was published in September 2018. The book has sold more than 75,000 copies, was an NPD Bookscan and Publisher’s Weekly Bestseller, broke the Top 40 on Amazon, and has more than 1,000 Five-star reviews. Mr. Handley and his nonspeaking son are also the authors of Underestimated: An Autism Miracle and co-produced the film SPELLERS, available now on YouTube.
How to End the Autism Epidemic is a reader-supported publication.
To receive new posts and support my work, consider becoming a free or paid subscriber.
-
Bruce Dowbiggin1 day agoWayne Gretzky’s Terrible, Awful Week.. And Soccer/ Football.
-
espionage13 hours agoWestern Campuses Help Build China’s Digital Dragnet With U.S. Tax Funds, Study Warns
-
Focal Points4 hours agoCommon Vaccines Linked to 38-50% Increased Risk of Dementia and Alzheimer’s
-
Opinion22 hours agoThe day the ‘King of rock ‘n’ roll saved the Arizona memorial
-
Agriculture23 hours agoCanada’s air quality among the best in the world
-
Business11 hours agoCanada invests $34 million in Chinese drones now considered to be ‘high security risks’
-
Health2 hours agoThe Data That Doesn’t Exist
-
Economy12 hours agoAffordable housing out of reach everywhere in Canada




